Metformin Hydrochloride Zentiva

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Zentiva, is a Biguanide presented as an oral tablet for oral use. It lowers blood glucose in adults with type 2 diabetes mellitus, improving glycemic control when used with diet and exercise.

GNH USA supplies Metformin Hydrochloride Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Metformin Hydrochloride is used in the management of hyperglycemia associated with type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes (impaired glucose tolerance): helps improve insulin sensitivity and may delay progression to overt diabetes. - Polycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity.

Metformin Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools that may be mild to moderate. - Metallic taste: transient alteration of taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Skin reactions: rash, urticaria, or Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas. - Renal impairment: worsening kidney function in susceptible patients.

When prescribing Metformin Hydrochloride, clinicians should consider several safety measures.

- Renal function: assess eGFR before initiating and monitor periodically. - Lactic acidosis risk: avoid in patients with significant hepatic impairment, hypoxia, or acute heart failure. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Vitamin B12 monitoring: consider periodic assessment during long‑term therapy. - Pregnancy and lactation: use only if potential benefits justify the potential risks. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Metformin Hydrochloride can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined. - Cimetidine: can increase metformin plasma concentrations. - Alcohol abuse: heightens the risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics (especially thiazides): can affect renal clearance of metformin. - ACE inhibitors or ARBs: require monitoring of renal function and electrolytes. - Digoxin: may require dose adjustment due to altered renal handling.